GRPR and breast carcinoma: Particularly, the 18F-equipped variant was tested on T47D and MDA-MB-435 tumor cells (human breast cancer cell lines) showing higher uptake on the T47D cells than on the MDA-MB-435 tumor cells, maybe due to the higher GRPR expression of the T47D cells.